Steps to registration of an oral treatment for sleeping sickness

Nathalie Strub-Wourgaft¹, Antoine Tarral¹, Louise Burrows¹, Nona Ghazanfari², Guillermo Dol³

¹Drugs for Neglected Diseases Initiative, Geneva, Switzerland – on behalf of the wider fexinidazole for HAT team
²Tuberculosis and Neglected Tropical Disease Programme, Sanofi, France

Background

Research into the treatment of sleeping sickness treatment was initiated by DNDi at the request of MSF. Fexinidazole is the first new chemical entity brought by DNDi through all stages of the drug development pipeline and into patients, including three clinical studies involving 749 patients. This 10 day all-oral treatment (1800 mg per day for 4 days followed by 1200 mg per day for 6 days) for both stages of T. b. gambiense sleeping sickness (g-HAT), is a significant improvement upon previous treatments because it eliminates the need for systematic hospitalization and should remove the need for systematic lumbar punctures.

Methods

For high-priority medicines and vaccines for use outside the EU that address unmet medical needs or are of major public health interest, the European Medicines Agency (EMA) has in place a regulatory pathway for review of these products, Article 58. Article 58 is a regulatory process involving the EMA-CHMP (Committee for Medicinal Products for Human Use), the World Health Organization, and national regulators in target countries in evaluating medicines to the same standards as those marketed within the EU. In this case, the target countries were Democratic Republic of Congo and Uganda. Regulators, experts and observers from concerned endemic countries are invited to participate, to ensure that local knowledge and specific disease expertise is included in the scientific review.

Once the positive scientific opinion was granted by the EMA for fexinidazole, this process enabled national marketing authorisation or registration of a medicine at national level. WHO will develop guidelines for use; other endemic countries could then include fexinidazole into national policy and submit letters to WHO to request the product, which then facilitates supply to these countries.

In addition, fexinidazole was added to the prequalification list following the positive opinion and was submitted for inclusion in the WHO Essential Medicines List (EML).

Since fexinidazole is planned to be submitted to the FDA for registration, the DNDi team ran a mock GCP inspection in order to ensure full compliance with FDA regulatory requirements.

Results

- December 2017: dossier submitted to the EMA
- November 2018: EMA adopted a positive scientific opinion of fexinidazole
- November 2018: submission to EML
- December 2018: fexinidazole registered in DRC
- February 2019: added to the prequalification list

On-going & future trials

- FEX009 adults & children, all stages, in-and out-patients (including breastfeeding or pregnant women in the second or third trimester.)
- Phase IIIII T.b. rhodiense HAT planned for mid-2019 in Malawi and Uganda.
- Phase IV in preparation in DRC, South Sudan, Guinea and Angola; and in CAR with MSF.

Conclusion

Due to the involvement of in-country experts and WHO in the EMA Article 58 review process, this innovative mechanism facilitated registration of fexinidazole in DRC in just 39 days, with registration in Uganda expected shortly.

Thanks to this regulatory process, which was based on data collected in patients recruited by MSF in DRC and CAR, and by the PNLTHA, new g-HAT patients should shortly benefit from this simplified, short-course oral regimen, the second transformative therapeutic improvement delivered by DNDi for sleeping sickness patients.

For questions or comments contact: nstrub@dndi.org

Completed trials

<table>
<thead>
<tr>
<th>Trial population</th>
<th>Number of participants</th>
<th>Efficacy based on success rate</th>
<th>Serious TEAEs Subjects [% w/o events]</th>
</tr>
</thead>
<tbody>
<tr>
<td>*FEX004 Adults in-patients Stage 2</td>
<td>264 (+130 NECT)</td>
<td>91.2% (97.0-96 CI – 11.2 to – 6.6; p&lt;0.0001)</td>
<td>31 (12) [%] [51]</td>
</tr>
<tr>
<td>FEX005 Adults in-patients Stage 1, early stage 2</td>
<td>230</td>
<td>98.7% (96.2-99.7%)</td>
<td>20 (9) [%] [32]</td>
</tr>
<tr>
<td>FEX006 Children 26-14 in-patients All stages</td>
<td>125</td>
<td>97.6% (93.1-99.5%)</td>
<td>10 (8) [%] [14]</td>
</tr>
</tbody>
</table>

*Fexinidazole in nocturnal encephalitis combination treatment (MELT), first line therapy for late stage g-HAT, comparative non-inferiority pivotal study

From research to treatment

- **Expression of interest**
  - PQ listing
  - EMA listing
  - Positive Scientific Opinion
  - MA (DRC, Uganda)

- **Inclusion in agreement**
  - Donation
  - MA (DRC, Uganda)

- **Submission to WHO EML**
  - MA (DRC, Uganda)

- **Inclusion of fexinidazole in national policy and Letter of interest (other endemic countries)**
  - Treatment & PV protocols
  - WHO/NTD

- **Supply to countries**
  - Training

Partners

- **DNDi**
  - National control programmes of the Democratic Republic of the Congo and the Central African Republic
  - Swiss TPH

Donors

DNDi thanks its core and HAT campaign donors: Médecins sans Frontières, founding member of DNDi and core contributor; Bill & Melinda Gates Foundation, USA; UK aid, UK; Dutch Ministry of Foreign Affairs (DGIS), The Netherlands; Federal Ministry of Education and Research (BMBF) through KfW, Germany; Ministry of European and Foreign Affairs (MEAE), France; Norwegian Agency for Development Cooperation (Norad), Norway; Republic and Canton of Geneva, Internal Solidarity Office, Switzerland; Spanish Agency for International Development and Cooperation (AECID), Spain; Swiss Agency for Development and Cooperation (SDC), Switzerland; UBS Optimus Foundation, Switzerland; Brian Mercer Charitable Trust, UK; Stavros Niarchos Foundation, USA and other private foundations and individuals.

*This article is licensed under the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).*